CTMX Q1 2021 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M-67.8% YoY

Gross Profit

$16M100.0% margin

Operating Income

-$16M-97.8% margin

Net Income

-$16M-97.4% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-2.5%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$31M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$434M

Total Liabilities

$288M

Stockholders' Equity

$146M

Cash & Equivalents

$330M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$50M	-67.8%
Gross Profit	$16M	$50M	-67.8%
Operating Income	-$16M	-$3M	-459.5%
Net Income	-$16M	$12M	-227.4%